US-based clinical stage biopharmaceutical company Ambrx and China-based Zhejiang Medicine have partnered for development and commercialisation of an antibody drug conjugate (ADC), ARX788.
As per the terms of collaboration, both companies will advance the development of Ambrx’s site-specific ADC targeting Her2-positive breast cancer, with the ongoing development costs being funded by ZMC.
The commercialisation rights to the drug candidate in China will be assumed by ZMC and commercial rights outside of China will be retained by Ambrx, which is also eligible for sales-based royalties in the country.
Ambrx chief executive officer Lawson Macartney said the collaboration with ZMC and WuXi enables development of ARX788 for both breast cancer and gastric cancer indications.
"This collaboration allows Ambrx to further extend our pipeline of ADCs and gain access to the China market through our partnership with ZMC," Macartney added.
"Our experience with site-specific ADC technology has shown that we have the potential to create best-in-class therapeutic candidates, and we look forward to advancing ARX788 into the clinic to understand its full potential."
The manufacturing activities of the product for worldwide clinical and commercial needs will be carried out by ZMC.
Pharmaceutical, biotechnology and medical device R&D outsourcing company WuXi PharmaTech will supply integrated services, such as development and manufacturing of the toxin, antibody and ADC, pre-clinical development and clinical trials for ARX788.
Zhejiang Medicine chairman Chunbo Li said: "We will work with WuXi PharmaTech to accelerate the development and commercialisation of ARX788 in China to bring benefits to Her2-positive cancer patients."
Image: Excised human breast tissue, showing a stellate area of cancer. Photo courtesy of John Hayman.